2015 Dosage Pharmaceutical Companies 
PharmTech
JULY 28, 2025
SHOW MORE EMA is phasing out animal testing and is asking pharmaceutical companies to use new approach methodologies. 2015 35(9):971-5. Techniques like organ-on-a-chip and cell transformation assays provide cost-effective, human-relevant models for pharmacokinetics and toxicity studies. NC 3Rs Workshop. J Appl Toxicol.
European Pharmaceutical Review
OCTOBER 7, 2022
A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Slow-release formulations were a popular choice for manufacturers, as these varieties reduce the traditional dosage frequency for patients, who only need to take these medications say, once a week.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 25, 2022
Understanding both the significant competitive advantages that FDC products can offer, and the difficulties and potential pitfalls associated with development and manufacturing of FDC drugs in oral solid dosage forms is a critical first step for companies exploring this approach. Of those 131 approved FDCs, 98 were oral dosage forms.
pharmaphorum
JUNE 1, 2021
Pharmaceutical companies are accountable for ensuring that their medicine is safe when it comes into the hands of patients. It is estimated that the incidence of counterfeiting, illegal diversion and theft in the US increased by almost 70% between 2015 and 2019 driven mainly by a rise in internet sales. About the author .
ISPE
JULY 6, 2023
Because the use of CM is expected to continue to grow beyond the current most common implementation for small molecule drug product, the focus on the guidance has been on general concepts that can be applied to any technology, dosage form, or molecule type.
European Pharmaceutical Review
OCTOBER 19, 2022
Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment.
ISPE
JULY 5, 2023
For example, one pharmaceutical company that switched to CM reported a 50% reduction in operating costs, a 33% reduction in waste, an 80% reduction in manufacturing and testing cycle time, and a 66% reduction in time from testing to release. End-to-end continuous processes flow from starting materials to finished dosage forms.
Expert insights. Personalized for you.
Let's personalize your content